T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions.

The effects of the adaptive immune system on the cognitive performance and abnormal behaviors seen in mental disorders such as schizophrenia have never been documented. Here, we show that mice deprived of mature T cells manifested cognitive deficits and behavioral abnormalities, which were remediable by T cell restoration. T cell-based vaccination, using glatiramer acetate (copolymer-1, a weak agonist of numerous self-reactive T cells), can overcome the behavioral and cognitive abnormalities that accompany neurotransmitter imbalance induced by (+)dizocilpine maleate (MK-801) or amphetamine. The results, by suggesting that peripheral T cell deficit can lead to cognitive and behavioral impairment, highlight the importance of properly functioning adaptive immunity in the maintenance of mental activity and in coping with conditions leading to cognitive deficits. These findings point to critical factors likely to contribute to age- and AIDS-related dementias and might herald the development of a therapeutic vaccination for fighting off cognitive dysfunction and psychiatric conditions.

[1]  P. Linton,et al.  Age-related changes in lymphocyte development and function , 2004, Nature Immunology.

[2]  I. Whishaw,et al.  Immediate and long-lasting effects of MK-801 on motor activity, spatial navigation in a swimming pool and EEG in the rat , 2004, Psychopharmacology.

[3]  P. Fletcher,et al.  Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia , 2003, Schizophrenia Research.

[4]  M. Sela,et al.  Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Chi,et al.  Gene expression profile analyses of cortical dysplasia by cDNA arrays , 2003, Epilepsy Research.

[6]  P. Emson,et al.  Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[7]  M. Schwartz,et al.  Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma. , 2003, Investigative ophthalmology & visual science.

[8]  M. Koch,et al.  Neurodevelopmental animal models of schizophrenia: effects on prepulse inhibition. , 2003, Current molecular medicine.

[9]  M. Egan,et al.  Schizophrenia, III: brain-derived neurotropic factor and genetic risk. , 2003, The American journal of psychiatry.

[10]  E. D. Kloet,et al.  Hormones, brain and stress , 2003 .

[11]  M. Schwartz,et al.  Protective autoimmunity against the enemy within: fighting glutamate toxicity , 2003, Trends in Neurosciences.

[12]  S. Akselrod,et al.  Therapeutic vaccination for closed head injury. , 2003, Journal of neurotrauma.

[13]  K. Vogeley,et al.  Influence of genetic loading, obstetric complications and premorbid adjustment on brain morphology in schizophrenia: , 2003, European Archives of Psychiatry and Clinical Neuroscience.

[14]  E. Yoles,et al.  Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Hohlfeld,et al.  Neurotrophic cross‐talk between the nervous and immune systems: Implications for neurological diseases , 2003, Annals of neurology.

[16]  P. Jansen-Dürr,et al.  A Darwinian-evolutionary concept of age-related diseases , 2003, Experimental Gerontology.

[17]  J. Kleinman,et al.  Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia , 2003, Molecular Psychiatry.

[18]  A. Bassett,et al.  Fine Mapping of the Schizophrenia Susceptibility Locus on Chromosome 1q22 , 2003, Human Heredity.

[19]  H. Wekerle Immune protection of the brain--efficient and delicate. , 2002, The Journal of infectious diseases.

[20]  Michal Schwartz,et al.  Neuroprotective autoimmunity: Naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Hohlfeld,et al.  Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. , 2002, Brain : a journal of neurology.

[22]  Michal Schwartz,et al.  Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders. , 2002, Trends in molecular medicine.

[23]  A. Meshorer,et al.  Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system , 2002, Journal of Neuroimmunology.

[24]  J. Meador-Woodruff,et al.  Striatal Excitatory Amino Acid Transporter Transcript Expression in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder , 2002, Neuropsychopharmacology.

[25]  N. Farber,et al.  Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity , 2002, Molecular Psychiatry.

[26]  Hadas Schori,et al.  T-cell-based immunity counteracts the potential toxicity of glutamate in the central nervous system , 2001, Journal of Neuroimmunology.

[27]  A. Miller,et al.  The neuroimmunology of stress and depression. , 2001, Seminars in clinical neuropsychiatry.

[28]  C. Tamminga,et al.  Effects of Ketamine in Normal and Schizophrenic Volunteers , 2001, Neuropsychopharmacology.

[29]  E. Hauben,et al.  Neuronal Survival after CNS Insult Is Determined by a Genetically Encoded Autoimmune Response , 2001, The Journal of Neuroscience.

[30]  M. Schwartz,et al.  Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries. , 2001, Trends in molecular medicine.

[31]  H. Weiner,et al.  Protective Autoimmunity Is a Physiological Response to CNS Trauma , 2001, The Journal of Neuroscience.

[32]  J. Lieberman,et al.  Longitudinal study of brain morphology in first episode schizophrenia , 2001, Biological Psychiatry.

[33]  L A Wheeler,et al.  Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Deutsch,et al.  A Revised Excitotoxic Hypothesis of Schizophrenia: Therapeutic Implications , 2001, Clinical neuropharmacology.

[35]  Hadas Schori,et al.  Vaccination for Neuroprotection in the Mouse Optic Nerve: Implications for Optic Neuropathies , 2001, The Journal of Neuroscience.

[36]  D. Holtzman,et al.  BDNF Protects the Neonatal Brain from Hypoxic-Ischemic InjuryIn Vivo via the ERK Pathway , 2000, The Journal of Neuroscience.

[37]  M. Schwartz,et al.  T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Javitt Treatment of negative and cognitive symptoms , 1999, Current psychiatry reports.

[39]  J. Pierri,et al.  Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia , 1999, Biological Psychiatry.

[40]  S. Ögren,et al.  A Behavioral Analysis of the Spatial Learning Deficit Induced by the NMDA Receptor Antagonist MK-801 (Dizocilpine) in the Rat , 1999, Neuropsychopharmacology.

[41]  T. Nabeshima,et al.  Characterization of learning and memory deficits in C57BL/6 mice infected with LP-BM5, a murine model of AIDS , 1999, Journal of Neuroimmunology.

[42]  C. Pantelis,et al.  Hippocampal volume in first-episode psychoses and chronic schizophrenia: a high-resolution magnetic resonance imaging study. , 1999, Archives of general psychiatry.

[43]  Irun R. Cohen,et al.  Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy , 1999, Nature Medicine.

[44]  D. Hu,et al.  Effects of MK-801 on vicarious trial-and-error and reversal of olfactory discrimination learning in weanling rats , 1998, Behavioural Brain Research.

[45]  G. Weber-Luxenburger,et al.  Psychic trauma causing grossly reduced brain metabolism and cognitive deterioration , 1998, Neuropsychologia.

[46]  H. Amital,et al.  Autoimmunity and schizophrenia: an epiphenomenon or an etiology? , 1993, Israel journal of medical sciences.